← All sources
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Three-arm RCT in 120 healthy older adults (60–80 y): commercial NR+pterostilbene (NRPT) at recommended or double dose raised whole-blood NAD+ about 40% (1×) and 90% (2×) by 4 weeks versus placebo, sustained through 8 weeks, with no serious adverse events.
Design
- Arms: placebo, NRPT 1×, NRPT 2×; n = 120 (60–80 y); 8 weeks daily dosing
- Primary readout: whole-blood NAD+ concentration
NAD+ dynamics (abstract)
- ~+40% NAD+ vs placebo/baseline in 1× arm by week 4, sustained to week 8
- ~+90% NAD+ in 2× arm by week 4, sustained to week 8
- Placebo: no rise across visits
Evidence hygiene
Combination product (NR + pterostilbene)—do not relabel as pure NR monotherapy; sponsor-employed authors disclosed.
Publication
Dellinger RW, Santos SR, Morris M, et al. NPJ Aging Mech Dis. 2017 Dec 21;4:17. doi 10.1038/s41514-017-0016-9 (PubMed PMID 29184669; see PubMed erratum/citation thread for publisher corrections).
Outcomes
- NAD+ Level40% (Percent Change)
- NAD+ Level90% (Percent Change)